Resectable Pancreatic Cancer: Who Really Benefits From Resection?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The 1-year disease-related mortality after resection for pancreatic cancer is approximately 30%. This study examined potential preoperative parameters that would help avoid unnecessary surgery.
Among the patients resected at our institution from 1997 to 2006, a total of 228 underwent pancreatic resection for ductal adenocarcinoma. By means of a survival cutoff of 12 months, two groups were created: early death (ED) and long survivors. A logistic regression analysis was performed to identify perioperative predictors of ED.
Among 228 resected patients, postoperative mortality occurred in four cases (1.8%) that were excluded from the study. In the remaining 224 patients, 43 (19.2%) died of disease within 12 months from surgery (ED), and the remaining 181 (80.8%) had a longer survival. Multivariate analysis selected duration of preoperative symptoms >40 days, CA 19-9 > 200 U/mL, pathological grading G3–G4, and R2 resection as independent predictors of ED.
Duration of symptoms, CA 19-9 serum level, and pathological grading possibly retrieved by endoscopic ultrasound–guided biopsy can be preoperatively used to identify patients with disease that is not suitable for up-front surgery, even if deemed resectable by high-quality imaging.
- Zuckerman, DS, Ryan, DP (2007) Adjuvant therapy for pancreatic cancer: a review. Cancer 112: pp. 243-249 CrossRef
- Picozzi, VJ, Pisters, PW, Vickers, SM, Strasberg, SM (2008) Strength of the evidence: adjuvant therapy for resected pancreatic cancer (review). J Gastrointest Surg 12: pp. 657-661 CrossRef
- Takamori, H, Hiraoka, T, Kanemitsu, K (2006) Identification of prognostic factors associated with early mortality after surgical resection for pancreatic cancer—under-analysis of cumulative survival curve. World J Surg 30: pp. 213-218 CrossRef
- Kennedy, EP, Yeo, CJ (2007) The case for routine use of adjuvant therapy in pancreatic cancer (review). J Surg Oncol 95: pp. 597-603 CrossRef
- Burris HA III. Recent updates on the role of chemotherapy in pancreatic cancer (review). Semin Oncol. 2005;32(4 Suppl 6):S1–3.
- Springett, GM, Hoffe, SE (2008) Borderline resectable pancreatic cancer: on the edge of survival (review). Cancer Control 15: pp. 295-307
- AJCC cancer staging manual. Springer, New York
- Neoptolemos, JP, Stocken, DD, Friess, H (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: pp. 1200-1210 CrossRef
- Traverso, LW (2006) Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 20: pp. S446-S449 CrossRef
- Vento, P, Mustonen, H, Joensuu, T (2007) Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol 13: pp. 2945-2951
- Varadhachary, GR, Tamm, EP, Abbruzzese, JL (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy (review). Ann Surg Oncol 13: pp. 1035-1046 CrossRef
- Brunner, TB, Grabenbauer, GG, Meyer, T (2007) Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7: pp. 41 CrossRef
- Welsch, T, Büchler, MW, Schmidt, J (2008) [Surgery for pancreatic cancer]. Z Gastroenterol 46: pp. 1393-1403 CrossRef
- Page, S, Caputo, S, Kwiatkowski, F, Berard, P, Gouillat, C (2008) [Functional outcome and quality of life after pancreaticoduodenectomy]. J Chir 145: pp. 32-36 CrossRef
- Sperti, C, Pasquali, C, Catalini, S (1993) CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 52: pp. 137-141 CrossRef
- Schniewind, B, Bestmann, B, Henne-Bruns, D (2006) Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg 93: pp. 1099-1107 CrossRef
- Safi, F, Schlosser, W, Falkenreck, S, Beger, HG (1998) Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 45: pp. 253-259
- Ferrone, CR, Finkelstein, DM, Thayer, SP (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24: pp. 2897-2902 CrossRef
- Barugola, G, Falconi, M, Bettini, R (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP 8: pp. 132-140
- Takamori, H, Hiraoka, T, Kanemitsu, K, Tsuji, T (2004) Pancreatic liver metastases after curative resection combined with intraoperative radiation for pancreatic cancer. Hepatogastroenterology 51: pp. 1500-1503
- Farrow, B, Sugiyama, Y, Chen, A (2004) Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 239: pp. 763-769 CrossRef
- Wang, W, Abbruzzese, JL, Evans, DB, Chiao, PJ (1999) Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18: pp. 4554-4563 CrossRef
- Shibata, K, Matsumoto, T, Yada, K, Sasaki, A, Kitano, S (2005) Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas 31: pp. 69-73 CrossRef
- Micames, C, Jowell, PS, White, R (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs percutaneous FNA. Gastrointest Endosc 58: pp. 690-695 CrossRef
- Larghi, A, Verna, EC, Stavropoulos, SN (2004) EUS-guided Trucut needle biopsies in patients with solid pancreatic masses: a prospective study. Gastrointest Endosc 59: pp. 185-190 CrossRef
- Varadarajulu, S, Fraig, M, Schmulewitz, N (2004) of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. Endoscopy 36: pp. 397-401 CrossRef
- Wittmann, J, Kocjan, G, Sgouros, SN (2006) Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and Trucut needle biopsy: a prospective study. Cytopathology 17: pp. 27-33 CrossRef
- Eloubeidi, MA, Tamhane, A, Varadarajulu, S, Wilcox, CM (2006) Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc 63: pp. 622-629 CrossRef
- Iglesias-Garcia, J, Dominguez-Munoz, E, Lozano-Leon, A (2007) Impact of endoscopic ultrasound-guided fine needle biopsy for diagnosis of pancreatic masses. World J Gastroenterol 13: pp. 289-293
- Moore, MJ (2005) Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32: pp. 5-6 CrossRef
- Resectable Pancreatic Cancer: Who Really Benefits From Resection?
Annals of Surgical Oncology
Volume 16, Issue 12 , pp 3316-3322
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Chirurgia Generale B, Department of Surgery, University of Verona, Verona, Italy
- 2. Department of Pathology, University of Verona, Verona, Italy